Promus - Registry Experience at the Washington Hospital Center, Drug-eluting Stent (DES)
This trial is active, not recruiting.
|Condition||coronary artery disease|
|Sponsor||Medstar Research Institute|
|Start date||October 2009|
|End date||July 2012|
|Trial size||800 participants|
|Trial identifier||NCT01003795, P REWARDS|
Single-center registry of patients treated with at least one Promus, everolimus-eluting, Stent, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.
Patients treated with at least one Promus, everolimus-eluting, Stent
Evaluation of Major Adverse Cardiac Events (MACE) post Promus Stent implantation
time frame: Follow up
Male or female participants at least 18 years old.
Inclusion Criteria: - Patients, male or female, >18 years of age - Patients who received at least one Promus drug-eluting stent at the Washington Hospital Center Exclusion Criteria: - N/A
|Official title||P-REWARDS (Promus - Registry Experience at the Washington Hospital Center, DES)|
|Principal investigator||Ron Waksman, MD|
|Description||Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Promus® Stent for at least 1 year post initial stent implantation.|
Call for more information